Explaining racial differences in prostate cancer in the United States: Sociology or biology?

Prostate

Volumn 62, Issue 3, 2005, Pages 243-252

  Freedland, Stephen J ^a   Isaacs, William B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic; Prostate cancer; Race; Socioeconomic

Indexed keywords

ANDROGEN; FINASTERIDE; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANDROGEN SYNTHESIS; ARTICLE; BIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CAUCASIAN; CLINICAL TRIAL; DIET; EDUCATION; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC VARIABILITY; HEALTH CARE ACCESS; HUMAN; NEGRO; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; SOCIOECONOMICS; SOCIOLOGY; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; ATTITUDE TO HEALTH; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; PROSTATIC NEOPLASMS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 12344324620     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20052     Document Type: Article

References (120)

1. Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 2003;97(6):1507-1516.
2. Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, Gilliland F, Hankey B, Kolonel LN, Kosary C, Ross R, Severson R, West D. Prostate Cancer Trends 1973-1995. SEER Program, National Cancer Institute NIH Pub No 99-4543. Bethesda, MD. 1999.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5-26.
4. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL. Racial and ethnic differences in advanced-stage prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93(5):388-395.
5. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: A SEER (surveillance, epidemiology, and end results) program population-based study. Arch Intern Med 2002;162(17):1985-1993.
6. Kittles RA, Weiss KM. Race, ancestry, and genes: Implications for defining disease risk. Annu Rev Genomics Hum Genet 2003;4:33-67.
7. Price JH, Colvin TL, Smith D. Prostate cancer: Perceptions of African-American males. J Natl Med Assoc 1993;85(12):941-947.
8. Demark-Wahnefried W, Strigo T, Catoe K, Conaway M, Brunetti M, Rimer BK, Robertson CN. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology 1995;46(3):346-351.
9. Polednak AP. Prostate cancer treatment in black and white men: The need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc 1998;90(2):101-104.
10. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol 2002;168(6):2510-2515.
11. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 1998;16(9):3101-3104.
12. Roetzheim RG, Pal N, Tennant C, Voti L, Ayanian JZ, Schwabe A, Krischer JP. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst 1999;91(16):1409-1415.
13. Vijayakumar S, Weichselbaum R, Vaida F, Dale W, Hellman S. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am 1996;2(4):225.
14. Conlisk EA, Lengerich EJ, Demark-Wahnefried W, Schildkraut JM, Aldrich TE. Prostate cancer: Demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. Urology 1999;53(6):1194-1199.
15. Howard G, Anderson RT, Russell G, Howard VJ, Burke GL. Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol 2000;10(4):214-223.
16. Tarman GJ, Kane CJ, Moul JW, Thrasher JB, Foley JP, Wilhite D, Riffenburgh RH, Amling CL. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology 2000;56(6):1016-1020.
17. Brawley OW. The study of untreated syphilis in the negro male. Int J Radiat Oncol Biol Phys 1998;40(1):5-8.
18. Cowen ME, Kattan MW, Miles BJ. A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer 1996;78(9):1952-1957.
19. Myers RE. African American men, prostate cancer early detection examination use, and informed decision-making. Semin Oncol 1999;26(4):375-381.
20. Boyd MD, Weinrich SP, Weinrich M, Norton A. Obstacles to prostate cancer screening in African-American men. J Natl Black Nurses Assoc 2001;12(2):1-5.
21. Barber KR, Shaw R, Folts M, Taylor DK, Ryan A, Hughes M, Scott V, Abbott RR. Differences between African American and Caucasian men participating in a community-based prostate cancer screening program. J Community Health 1998;23(6):441-451.
22. Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 2003;98(3):496-503.
23. Wilkinson S, List M, Sinner M, Dai L, Chodak G. Educating African-American men about prostate cancer: Impact on awareness and knowledge. Urology 2003;61(2):308-313.
24. Moul JW. Screening for prostate cancer in African Americans. Curr Urol Rep 2000;1(1):57-64.
25. Powell IJ, Heilbrun L, Littrup PL, Franklin A, Parzuchowski J, Gelfand D, Sakr W. Outcome of African American men screened for prostate cancer: The Detroit Education and Early Detection Study. J Urol 1997;158(1):146-149.
26. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: A case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991;2(2):85-94.
27. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85(19):1571-1579.
28. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: Current status. J Natl Cancer Inst 1999;91(5):414-428.
29. Pandalai PK, Pilat MJ, Yamazaki K, Naik H, Pienta KJ. The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth. Anticancer Res 1996;16(2):815-820.
30. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995;87(19):1456-1462.
31. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001;91(4):737-743.
32. Neumark-Sztainer D, Story M, Hannan PJ, Croll J. Overweight status and eating patterns among adolescents: Where do youths stand in comparison with the healthy people 2010 objectives? Am J Public Health 2002;92(5):844-851.
33. Patterson BH, Harlan LC, Block G, Kahle L. Food choices of whites, blacks, and Hispanics: Data from the 1987 National Health Interview Survey. Nutr Cancer 1995;23(2):105-119.
34. Lytle LA, Himes JH, Feldman H, Zive M, Dwyer J, Hoelscher D, Webber L, Yang M. Nutrient intake over time in a multi-ethnic sample of youth. Public Health Nutr 2002;5(2):319-328.
35. Gans KM, Burkholder GJ, Risica PM, Lasater TM. Baseline fat-related dietary behaviors of white, Hispanic and black participants in a cholesterol screening and education project in New England. J Am Diet Assoc 2003;103(6):699-706.
36. Thompson B, Demark-Wahnefried W, Taylor G, McClelland JW, Stables G, Havas S, Feng Z, Topor M, Heimendinger J, Reynolds KD, Cohen N. Baseline fruit and vegetable intake among adults in seven 5 a day study centers located in diverse geographic areas. J Am Diet Assoc 1999;99(10):1241-1248.
37. Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC, Potosky AL. Racial differences in initial treatment for clinically localized prostate cancer. J Gen Intern Med 2003;18(10):845-853.
38. Merrill RM. Nonaggressive management of white and black prostate cancer patients in the United States. Prostate Cancer Prostatic Dis 2000;3(2):94-99.
39. Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Factors associated with initial therapy for clinically localized prostate cancer: Prostate cancer outcomes study. J Natl Cancer Inst 2001;93(24):1864-1871.
40. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000;88(5):1122-1130.
41. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-789.
42. Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology 2000;55(5):730-735.
43. Sohayda CJ, Kupelian PA, Altsman KA, Klein EA. Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol 1999;162(4):1331-1336.
44. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol 2000;163(1):143-145.
45. Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology 2000;56(1):87-91.
46. Moul JW, Douglas TH, McCarthy WF, McLeod DG. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996;155(5):1667-1673.
47. Powell IJ, Dey J, Dudley A, Pontes JE, Cher ML, Sakr W, Grignon DJ, Wood DP. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: A multivariable analysis. Urology 2002;59(6):907-912.
48. Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC, Terris MK, Aronson WJ. Race as an outcome predictor after radical prostatectomy. Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 2002;60(4):670-674.
49. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, Grossfeld GD, Carroll PR. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001;166(4):1322-1327.
50. Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Richie JP, D'Amico AV. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 2002;20(12):2863-2868.
51. Bianco FJ Jr., Kattan MW, Scardino PT, Powell IJ, Pontes JE, Wood DP Jr. Radical prostatectomy nomograms in black American men: Accuracy and applicability. J Urol 2003;170(1):73-76.
52. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90(10):766-771.
53. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-1507.
54. Bianco FJ Jr., Wood DP Jr., Grignon DJ, Sakr WA, Pontes JE, Powell IJ. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. J Urol 2002;168(2):479-482.
55. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr., Amling CL, Elashoff D, Terris MK. Impact of obesity on biochemical control following radical prostatectomy for clinically localized prostate cancer. J Clin Oncol 2004;2263:446-453.
56. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The continuing epidemic of obesity in the United States. JAMA 2000;284:1650-1651.
57. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001;58(5):723-728.
58. Krongrad A, Lai H, Lai S. Disease specific death after external beam radiation of prostate cancer. Prostate Cancer Prostatic Dis 1998;1(3):144-147.
59. Kim JA, Kuban DA, el-Mahdi AM, Schellhammer PF. Carcinoma of the prostate: Race as a prognostic indicator in definitive radiation therapy. Radiology 1995;194(2):545-549.
60. Aziz H, Rotman M, Thelmo W, Chen P, Choi KN, Khil SU, Laungani GB, Brandys M, Ayr G, Macchia RJ. Radiation-treated carcinoma of prostate. Comparison of survival of black and white patients by Gleason's grading system. Am J Clin Oncol 1988;11(2):166-171.
61. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: Year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys 2003;57(3):629-634.
62. Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: Multivariate and matched-pair analyses. Int J Radiat Oncol Biol Phys 2002;53(2):282-289.
63. Young CD, Lewis P, Weinberg V, Lee TT, Coleman CW, Roach M III. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy. Semin Urol Oncol 2000;18(2):121-126.
64. Hart KB, Porter AT, Shamsa F, Chuba PJ, Pontes JE, Forman JD. The influence of race on the efficacy of curative radiation therapy for carcinoma of the prostate. Semin Urol Oncol 1998;16(4):227-231.
65. Zagars GK, Pollack A, Pettaway CA. Prostate cancer in African-American men: Outcome following radiation therapy with or without adjuvant androgen ablation. Int J Radiat Oncol Biol Phys 1998;42(3):517-523.
66. Connell PP, Ignacio L, Haraf D, Awan AM, Halpern H, Abdalla I, Nautiyal J, Jani AB, Weichselbaum RR, Vijayakumar S. Equivalent racial outcome after conformal radiotherapy for prostate cancer: A single departmental experience. J Clin Oncol 2001;19(1):54-61.
67. Roach M III, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol 2003;169(1):245-250.
68. Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: Radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology 2002;225(2):420-426.
69. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76(1):45-48.
70. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: A longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002;11(10 Pt 1):1041-1047.
71. Beilin J, Ball EM, Favaloro JM, Zajac JD. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25(1):85-96.
72. Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000;9(2):267-274.
73. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22(15):3181-3186.
74. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92(24):2009-2017.
75. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55(9):1937-1940.
76. Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol 2002;20(17):3599-3604.
77. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 1999;53(2):378-380.
78. Gaston KE, Kim D, Singh S, Ford OH III, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 2003;170(3):990-993.
79. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68(1):82-91.
80. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, Griffin R, Williams T, Ukoli F, Adams-Campbell L, Kwagyan J, Isaacs W, Freeman V, Dunston GM. CYP3A4-V and prostate cancer in African Americans: Causal or confounding association because of population stratification? Hum Genet 2002;110(6):553-560.
81. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, McBride S, Deitz A, Malko wicz SB, Ofori-Adjei D, Gueye SM, Rebbeck TR. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002;54(1):13-21.
82. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res 1995;55(18):3973-3975.
83. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, Reichardt JK. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk. Prostate 1997;33(1):9-12.
84. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995;274(16):1277-1281.
85. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996;335(5):304-310.
86. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-224.
87. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: Current perspectives and future directions. Prostate 2002;52(3):213-235.
88. Giovannucci E. Is the androgen receptor CAG repeat length significant for prostate cancer? Cancer Epidemiol Biomarkers Prev 2002;11(10 Pt 1):985-986.
89. Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11(10 Pt 1):1033-1040.
90. Stanford JL, Just JJ, Gibbs M, Widdund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk. Cancer Res 1997;57(6):1194-1198.
91. Miller EA, Stanford JL, Hsu L, Noonan E, Ostrander EA. Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate 2001;48(3):200-205.
92. Correa-Cerro L, Wohr G, Haussler J, Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P, Just W, Paiss T, Cantu JM, Vogel W. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999;7(3):357-362.
93. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999;81(4):672-676.
94. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94(7):3320-3323.
95. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89(2):166-170.
96. Beilin J, Harewood L, Frydenberg M, Mameghan H, Martyres RF, Farish SJ, Yue C, Deam DR, Byron KA, Zajac JD. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer 2001;92(4):941-949.
97. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 2000;60(18):5111-5116.
98. Panz VR, Joffe BI, Spitz I, Lindenberg T, Farkas A, Haffejee M. Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men. Endocrine 2001;15(2):213-216.
99. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92(5):1130-1137.
100. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset. J Clin Endocrinol Metab 1996;81(12):4400-4405.
101. Powell IJ, Schwartz K, Hussain M. Removal of the financial barrier to health care: Does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology 1995;46(6):825-830.
102. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52(1):8-22.
103. Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE, Tricoli JV. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer. Urology 2001;58(4):614-618.
104. Platz EA, Pollak MN, Rimm EB, Majeed N, Tao Y, Willett WC, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 1999;8(12):1107-1110.
105. Tricoli JV, Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pinover WH, Hanks GE. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 1999;54(1):178-182.
106. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279(5350):563-566.
107. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94(14):1099-1106.
108. Lee KW, Cohen P. Nuclear effects: Unexpected intracellular actions of insulin-like growth factor binding protein-3. J Endocrinol 2002;175(1):33-40.
109. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol 2003;253(2):165-174.
110. Prinsac GS, Birch L, Habermann H, Chang WY, Tebeau C, Putz O, Bieberich C. Influence of neonatal estrogens on rat prostate development. Reprod Fertil Dev 2001;13(4):241-252.
111. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with alphaERKO and betaERKO mice. Cancer Res 2001;61(16):6089-6097.
112. vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Ganjam VK, Parmigiani S, Welshons WV. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 1997;94(5):2056-2061.
113. O'Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-ethnicity-specific variation in multiple-marker biochemical screening: Alpha-fetoprotein, hCG, and estriol. Obstet Gynecol 1997;89(3):355-358.
114. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: Potential effects on male offspring. Br J Cancer 1988;57(2):216-218.
115. Woodson K, Hayes R, Wideroff L, Villaruz L, Tangrea J. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US blacks and whites. Prostate 2003;55(3):199-205.
116. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32(2):321-325.
117. Nickel RG, Willadsen SA, Freidhoff LR, Huang SK, Caraballo L, Naidu RP, Levett P, Blumenthal M, Banks-Schlegel S, Bleecker E, Beaty T, Ober C, Barnes KC. Determination of Duffy genotypes in three populations of African descent using PCR and sequence-specific oligonucleotides. Hum Immunol 1999;60(8):738-742.
118. Lentsch AB. The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? Faseb J 2002;16(9):1093-1095.
119. Dawson TC, Lentsch AB, Wang Z, Cowhig JE, Rot A, Maeda N, Peiper SC. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 2000;96(5):1681-1684.
120. Alexander GA, Brawley OW. Prostate cancer treatment outcome in blacks and whites: A summary of the literature. Semin Urol Oncol 1998;16(4):232-234.